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Abstract
In a previous paper we showed that bradykinin (BK), interacting with its B2 receptor, inhibits proximal tubule Na
+-ATPase activity but does
not change (Na++K+)ATPase activity. The aim of this paper was to investigate the molecular mechanisms involved in B2-mediated modulation of
proximal tubule Na+-ATPase by BK. To abolish B1 receptor-mediated effects, all experiments were carried out in the presence of (Arg-Pro-Pro-
Gly-Phe-Ser-Pro-Leu), des-Arg9-[Leu8]-BK (DALBK), a specific antagonist of B1 receptor. A dual effect on the Na
+-ATPase activity through the
B2 receptor was found: short incubation times (1–10 min) stimulate the enzyme activity; long incubation times (10–60 min) inhibit it. The
stimulatory effect of BK is mediated by activation of phosphoinositide-specific phospholipase C β (PI-PLCβ)/protein kinase C (PKC); its
inhibitory action is mediated by Ca2+-independent phospholipase A2 (iPLA2). Prior activation of the PI-PLCβ/PKC pathway is required to activate
the iPLA2-mediated inhibitory phase. These results reveal a new mechanism by which BK can modulate renal sodium excretion: coupling between
B2 receptor and activation of membrane-associated iPLA2.
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Bradykinin (BK) is a component of the kallikrein–kinin
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tide-specific phospholipase C β; PKC, protein kinase C; PLA2, phospholipase
A2; PMA, phorbol 12-myristate 13-acetate; sPLA2, secretory PLA2; TLC, thin
layer chromatography; Tris, tris(hydroxymethyl)aminomethane
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doi:10.1016/j.bbamem.2008.01.017as blood pressure regulation [1]. These effects are associated with
the modulation of renal sodium excretion and are due, at least in
part, to modulation of transcellular sodium reabsorption [2].
Because most filtered sodium is reabsorbed in proximal tubules,
small changes in this process will have major consequences for
the overall sodium metabolism in the body. Furthermore, the
pathologies correlated to renal sodium excretion, such as primary
hypertension, have been associated with changes in proximal
tubule sodium reabsorption [3].
The limiting step for sodium reabsorption in the proximal
tubule is its active basolateral transport through the primary
active transporters [4]. Two primary active transporters in-
volved in the genesis of the Na+ electrochemical gradient have
been described: ouabain-sensitive (Na++K+)ATPase and oua-
bain-insensitive, furosemide-sensitive Na+-ATPase [5–7]. In a
previous paper our group showed that BK inhibits proximal
tubule Na+-ATPase activity through B2 receptors but does not
change the (Na++K+)ATPase activity [8]. This inhibitory effect
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with B2-mediated natriuresis and diuresis [9].
The effects of BKaremediated by two types of kinin receptors:
B1 and B2 [10,11]. Normally, B2 receptors are constitutively
expressed in tissues; B1 is expressed only in specific situations.
Both receptors have seven transmembrane domains and belong to
the family of G protein-coupled receptors. Previous studies in-
dicate that the B2-mediated bradykinin effects on renal sodium
excretion are, at least in part, mediated by activation of phos-
pholipase A2 (PLA2) [12]. However, the type of PLA2 and the
molecular mechanism underlying the coupling among bradykinin
receptor, PLA2 activity and active sodium transporters are still to
be determined. There are three classes of PLA2, based on the Ca
2+
requirement for enzymatic activity: secretory PLA2 (sPLA2),
which requiresmillimolar concentrations of Ca2+; cytosolic PLA2
(cPLA2), which requires micromolar concentrations of Ca
2+; and
Ca2+-independent PLA2 (iPLA2) [13]. So far nothing is known
about the regulation of iPLA2 by peptide hormones, in particular
BK.
The aim of this studywas to test the involvement ofmembrane-
associated iPLA2 on the B2-mediated BK inhibition of proximal
tubule Na+-ATPase activity. To avoid the PLA2 present in the
cytosol fraction we used basolateral membranes (BLM) isolated
from porcine proximal tubule cells. This preparation contains
components of different signaling pathways including G proteins,
phospholipases and protein kinases [14–16]. Interestingly, it was
observed that BK at the B2 receptor has a dual effect on the Na
+-
ATPase activity that is mediated by sequential activation of the
membrane-associated phosphoinositide-specific phospholipase C
β (PI-PLCβ)/protein kinase C (PKC) and iPLA2 pathways. These
results reveal an additional mechanism by which BK can mo-
dulate renal sodium excretion: coupling between B2 receptor and
membrane-associated iPLA2 activation.
2. Materials and methods
2.1. Materials
ATP, ouabain, furosemide, EGTA, HEPES, Tris, bradykinin (Arg-Pro-Pro-
Gly-Phe-Ser-Pro-Phe-Arg), des-Arg9-[Leu8]-BK (DALBK), diclofenac sodium
salt, indomethacin, and 1,2-dipalmitoyl-phosphatidylcholine (DPPC) were pur-
chased from Sigma Chemical Co., St. Louis, MO, USA. Percoll was from
Pharmacia Biotech, Uppsala, Sweden. Palmitoyl trifluoromethyl ketone
(PACOCF3), N-(p-amylcinnamoyl) anthranilic acid (ACA) and quinacrine
dihydrochloride (Mepacrine) were purchased from Calbiochem-Novabiochem
Co., San Diego, CA, USA. Rabbit polyclonal antibody anti-iPLA2 was pur-
chased from Upstate Biotechnology, Lake Placid, NY, USA and peroxidase-
conjugated sheep anti-rabbit antibody was purchased from Calbiochem, San
Diego, CA, USA. All other reagents were of the highest purity available. [32P]Pi
was obtained from the Institute of Energetic and Nuclear Research, São Paulo,
SP, Brazil. L-3-phosphatidylcholine, 1-palmitoyl-2-[1-14C]palmitoyl was
obtained from Amersham Pharmacia Biotech UK Limited. Silica gel 60 thin
layer chromatography (TLC) plates and all solvents used were obtained from
Merck KGaA, Darmstadt. All solutions were prepared with deionized glass-
distilled water. [γ-32P]ATP was prepared as described by Maia et al. [17].
2.2. Isolated basolateral membranes
The basolateral membranes (BLM) of proximal tubules were isolated and
purified using the Percoll gradient method as described previously [18]. The
membrane preparation was resuspended in 250 mM sucrose at a final con-centration of 5–10 mg protein/ml and stored at −20 °C. The (Na++K+)ATPase
activity, a marker for basolateral membranes, was 10–12 times higher than the
activity found in the cortex. Residual contamination with other subcellular
membrane fractions was minimal. Protein concentration was determined by the
Folin phenol method [19] using bovine serum albumin as a standard.
2.3. Measurement of ATPase activity
The composition of the assay medium for the measurement of the Na+-
ATPase activity (0.1 ml) was: 4 mM MgCl2; 4 mM ATP (specific activity about
104 Bq/nmol ATP); 20 mM HEPES–Tris (pH 7.0); 90 mM NaCl; 10−8 M
DALBK; and 1 mM ouabain. The ATPase activity was measured according to
the method described by Grubmeyer and Penefsky [20]. The reaction was started
by the addition of the membranes to the assay medium to a final protein
concentration of 0.3–0.5 mg/ml, and stopped after 10 min by the addition of
0.1 N HCl-activated charcoal. The [32P]Pi released was measured in an aliquot
of the supernatant obtained after centrifugation of the charcoal suspension for
5 min at 2000 rpm in a clinical centrifuge. Spontaneous hydrolysis of [γ-32P]
ATP was measured simultaneously in tubes to which protein was added after the
acid. The Na+-ATPase activity was calculated from the difference between the
[32P]Pi released in the absence and in the presence of 2 mM furosemide, both in
the presence of 1 mM ouabain [21].
2.4. Measurement of PLA2 activity
The PLA2 activity was measured according to the method described by Yang
et al. [22]. The assay utilized 100 μM DPPC (containing 5.0×105 cpm of L-3-
phosphatidylcholine, 1-palmitoyl-2-[1-14C]palmitoyl) in 0.8 mM Triton X-100,
mixed micelles in 200 mM HEPES (pH 7.0), 5 mM EDTA, 2 mM DTT, 1 mM
ATP and 10−8 M DALBK. The reaction was started by the addition of isolated
basolateral membranes to a final protein concentration of 0.3 mg/ml. The free
fatty acid released was extracted from isolated BLM following the method
of Horwitz and Perlman, modified by Malaquias and Oliveira [23]. The lipid
samples were applied to TLC silica gel plates along with phospholipid stan-
dards. Prior to lipid loading, the plates were activated at 110 °C for 10 min. TLC
was developed in two solvent mixtures: CHCl3/CH3OH/H2O (65:35:5 v/v) and
C6H14/CH3CH2OCH2CH3/CHOOH (90:60:4 v/v). The region of the TLC plate
containing free fatty acid was identified with iodine vapor and scraped into
scintillation vials. The radioactivity was quantified in a liquid scintillation
counter (Packard Tri-Carb model A2100TR, Illinois, USA).
2.5. Measurement of PLC activity
BLM phospholipids were labeled by incubating them at 37 °C for 4 h with
4 mM ATP (40,000 cpm/nmol [γ-32P]ATP), 4 mMMgCl2, 20 mMHEPES–Tris
(pH 7.0) and 90 mM NaCl. The reaction was started by the addition of 10−9 M
BK or vehicle (10 mM HCl). Total phospholipids were extracted from isolated
BLM following the method of Horwitz and Perlman, modified byMalaquias and
Oliveira [23]. Lipid samples were dissolved in 20 μl of a mixture of CHCl3/
CH3OH/H2O (75:25:2 v/v) and spotted along with phospholipid standards
on silica gel G plates that were pre-activated at 110 °C for 10 min. TLC was
developed in solvent mixture CHCl3/CH3OH/CH3COCH3/CH3COOH/ H2O
(40:13:15:12:8 v/v). Labeled PIP2 spots were visualized by exposure to I2
vapors and scraped off the plate into scintillation vials. The radioactivity was
quantified in a liquid scintillation counter.
2.6. Measurement of PKC activity
The PKC activity of isolated BLM was measured by calphostin C (Cph C)-
sensitive incorporation of 32Pi from [γ32-P]ATP (7 μCi/μmol), using histone as
substrate. The composition of the reaction medium was: 4 mM MgCl2, 20 mM
HEPES–Tris (pH 7.0), 1.5 mg/ml histone and 0.7 mg/ml protein. The reaction
was stopped with 40% TCA and the sample immediately placed on ice. An
aliquot (0.1 ml) was filtered through a Millipore filter (0.45 μm) and washed
with ice-cold 20% TCA solution and 0.1 M phosphate buffer (pH 7.0). The
radioactivity was quantified by liquid scintillation counting (Packard Tri-Carb
2100 TR). The specific PKC activity was calculated from the difference between
Fig. 1. Modulation of the inhibitory effect of 10−9 M BK on Na+-ATPase
activity by PLA2 inhibitors. The Na
+-ATPase activity in proximal tubules was
measured as described in Materials and methods. A, Quinacrine and ACA
concentrations were increased from 10−10 to 10−5 M in the presence of 10−9 M
BK (n=10). B, 10−6 M PACOCF3 and 10
−6 M BELwere added where indicated
(n=9). Data are shown as means±SE. ⁎Statistically significant when compared
to control ( pb0.05).
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ester, phorbol myristate acetate (PMA), was used as the activator of PKC.
2.7. Immunoblotting
The presence in basolateral membranes of iPLA2 protein was determined by
immunoblotting. Proteins were resolved on 7.5% SDS-PAGE gels and trans-
ferred to nitrocellulose membranes (Amersham Biosciences, Piscataway, NJ,
USA) according to the manufacturer's instructions. The membranes were
incubated overnight with the anti-iPLA2 antibody 1:500 with agitation at 4 °C,
washed three times and then incubated with anti-rabbit peroxidase-conjugated
antibody (Amersham Pharmacia) diluted 1:5000 in PBST plus 3% non-fat dry
milk for 1 h at room temperature, with agitation. After antibody labeling, detec-
tion was performed with ECL (Amersham Biosciences, Piscataway, NJ, USA).
2.8. Data analysis
The means were compared by one-way variance analysis (ANOVA) taking
into account the treatment of the experimental groups. The magnitudes of the
differences were evaluated using the multiple comparative Bonferroni test. The
data are presented as the mean±standard error. The n corresponds to the results
obtained from different basolateral membrane preparations.
3. Results
In a previous paper we showed that BK has a biphasic effect
on proximal tubule Na+-ATPase activity, with an inhibitory
effect mediated by B2 receptor and a stimulatory effect mediated
by B1 receptor [8]. Here we examined the possibility that the
B2-mediated inhibition of the Na
+-ATPase by BK could be
mediated by activation of PLA2. All experiments were carried
out in the presence of 10−8 M DALBK, a specific antagonist of
B1 receptor that completely abolishes the B1-mediated stimula-
tion of enzyme activity by BK [24]. The pre-incubation of the
enzyme with 10−9 M BK for 30 min decreased Na+-ATPase
activity from 27.5±3.1 to 13.9±2.5 nmol Pi×mg−1 ×min−1
(Fig. 1A). This effect was completely abolished by the PLA2
non-specific inhibitors, quinacrine and ACA, at 10−8 M.
Since all experiments were done in the absence of added Ca2+
and in the presence of 1 mM EGTA, this result indicates the
involvement of Ca2+-independent PLA2 (iPLA2) in the BK
effect. To test this hypothesis, the experiments were performed
in the presence of PACOCF3 and bromoenol lactone (BEL),
specific inhibitors of iPLA2 [25] (Fig. 1B). PACOCF3 and BEL
at 10−6 M completely reversed the inhibitory effect of BK
10−9 M on Na+-ATPase activity. Quinacrine, ACA, BEL and
PACOCF3 at 10
−6 M did not affect Na+-ATPase activity when
added separately, without BK (data not shown).
To determine the presence of iPLA2 in BLM we measured its
activity directly (Fig. 2). The isolated BLM were incubated with
10−9 M BK for different times (1, 3, 5, 10, 20 and 30 min). After
the reaction, the phospholipids were separated and PLA2 ac-
tivity was quantified. Fig. 2A shows the effect of 10−9 M BK on
PLA2 activity. BK increased PLA2 activity by 120% with the
maximal effect observed at 5 min. This was completely reversed
after 20 min of incubation. To further confirm the presence of
iPLA2 in BLM, immunoblotting using rabbit anti-iPLA2
antibody was carried out (Fig. 2B). A band at 85 kDa which
corresponds to the correct molecular mass for iPLA2 [26] was
detected in cortex homogenate and BLM. Rat cerebellum wasused as a positive control for iPLA2 [27]. The correlation
between the effect of BK on Na+-ATPase activity and activation
of iPLA2 was tested in the next experimental group (Fig. 2C).
The BK-stimulated PLA2 activity was completely reversed by
PACOCF3 and BEL at 10
−6 M, specific inhibitors of iPLA2
(Fig. 2C). Furthermore, it was observed that both PACOCF3 and
BEL completely abolished the basal PLA2 activity (data not
shown).
B2 receptor belongs to the G protein-coupled receptor family,
and consequently, is associated with trimeric G proteins [11]. To
confirm that the effect of 10−9 M BK on the BLM-associated
iPLA2 is mediated by B2 receptor, we performed experiments in
the presence of 10−6 M HOE140, a specific antagonist for B2,
and 10−6 M GDPβS, a non-hydrolyzable GDP analog that
inhibits trimeric G proteins (Fig. 2C). Both compounds com-
pletely abolished the stimulatory effect of BK on the BLM-
associated iPLA2 activity. Similarly, these compounds abol-
ished the inhibitory effect of 10−9 M BK on Na+-ATPase
activity (data not shown).
It is well known that PLA2 catalyzes the hydrolysis of the sn-2
position of membrane glycerophospholipids to liberate arachi-
donic acid (AA) [13]. The increase in concentration of AA from
Fig. 2. Involvement of iPLA2 on the BK-mediated inhibition of Na
+-ATPase activity. A, Time course of the effect of BK on PLA2 activity in proximal tubule BLM.
BK-induced change in PLA2 activity was calculated from the difference between fatty acid formed in the presence and in the absence of 10
−9 M BK and expressed as a
percentage of the increase, for the times shown. The PLA2 activity was measured as described inMaterials and methods (n=10). B, Immunoblot for detection of iPLA2
in proximal tubule BLM. Membrane proteins were separated on 7.5% SDS-PAGE and then transferred to a nitrocellulose membrane and incubated with anti-iPLA2
antibody as described in Materials and methods. (1) Positive control (rat cerebellum); (2, 3) 50 μg of two different preparations of isolated BLM proteins; and (4, 5)
50 μg of protein obtained from two different preparations of cortex homogenate (n=3). C, Modulation of the stimulatory effect of 10−9 M BK on PLA2 activity by
10−6 M PACOCF3, 10
−6 M BEL, 10−6 M HOE140 and 10−6 M GDPβS. The enzyme activity was measured as described in Materials and methods (n=6). D, Dose-
dependent effect of AA on Na+-ATPase activity. The concentration of AAwas increased from 10−12 to 10−8 M and this effect is similar and non-additive to the BK
effect (open circle). Controls are represented by open triangle. The enzyme activity was measured as described in Materials and methods (n=13). Data are shown as
means±SE. ⁎Statistically significant when compared to respective controls ( pb0.05).
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(Fig. 2D). This effect is similar and non-additive to the BK effect.
Fig. 3 shows the modulation of the effect of 10−9 M BK or
10−8 M AA on Na+-ATPase activity by the cyclooxygenase
(COX) inhibitors, 10−9 M diclofenac and 10−6 M indomethacin.
It was observed that the inhibitory effect of BK or AA was
completely reversed by both COX inhibitors. The addition of
diclofenac or indomethacin alone did not change the Na+-ATPase
activity (data not shown).
These data indicate that a membrane-associated, Ca2+-
independent PLA2 isoform is involved in the inhibitory effect
of BK on Na+-ATPase activity.
Fig. 4A shows the effect of BK on Na+-ATPase activity in
the presence of 10−8 M DALBK, a specific antagonist of B1
receptor. BK at 10−9 M had a dual effect on Na+-ATPase
activity. The incubation of the enzyme with 10−9 M BK for a
short time (1–10 min) increased Na+-ATPase activity, with a
maximal effect observed at 1 min. After 15 min of incubation,
10−9 M BK inhibited the enzyme activity with a maximal effectobserved at 30 min. This inhibitory effect was maintained for at
least 60 min (data not shown). To be sure that the stimulatory
effect is mediated by B2 receptor, we tested the effect of 10
−6 M
HOE140, a specific antagonist for B2 (Fig. 4B). Under these
conditions, we observed that the stimulatory effect of 10−9 M
BK observed after the incubation of the enzyme for 1 min was
completely abolished. These data show that interaction of BK
with B2 receptor activates different pathways. Recently, we
showed that the activation of the PI-PLCβ/PKC pathway leads
to activation of proximal tubule Na+-ATPase activity [15].
Fig. 4B shows the effect of 10−9 M BK on Na+-ATPase activity
during 1 min of incubation with 10−8 M Cph C, an inhibitor of
PKC, and 5×10−8 M U73122, a specific inhibitor of PI-PLCβ.
Both compounds completely abolished the stimulatory effect of
BK.
Fig. 5 shows the effect of 10−9 M BK on PI-PLCβ and PKC
activities in BLM. BK increased both enzyme activities after a
short period of incubation. The maximal effect for PI-PLCβwas
observed at 30 s (Fig. 5A) and for PKC at 3 min (Fig. 5B),
Fig. 3. COX inhibitors abolish the effect of BK and AA on Na+-ATPase activity.
Na+-ATPase activity wasmeasured as described inMaterials andmethods (n=4).
10−9 M BK, 10−8 M AA, 10−9 M diclofenac or 10−6 M indomethacin was added
where indicated. Data are shown as means±SE. ⁎Statistically significant when
compared to respective controls ( pb0.05).
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effect of BK on PI-PLCβ and PKC was completely abolished
by addition of 5×10−8 M U73122 (data not shown).Fig. 4. Dual effect of 10−9 M BK on Na+-ATPase activity. A, Time course of the
effect of BK in the presence of 10−8 M DALBK. Na+-ATPase activity was
measured as described in Materials and methods (n=7). B, Modulation of the
stimulatory effect of 10−9 M BK (1 min of reaction) on Na+-ATPase activity by
10−6 MHOE140, 5×10−8 MU73122 and 10−8 MCph C (n=6). Data are shown
as means±SE. ⁎Statistically significant when compared to respective controls
( pb0.05).
Fig. 5. BK activates the PI-PLCβ/PKC pathway. A, Time course of the effect of
10−9 M BK on PLC activity (n=4). B, Time course of the effect of 10−9 M BK
on PKC activity (n=6). The enzyme activities were measured as described in
Materials and methods. Data are shown as means±SE. ⁎Statistically significant
when compared to respective controls ( pb0.05).The next experiments were carried out to study the require-
ment for prior activation of the PI-PLCβ/PKC pathway on
PLA2-mediated inhibition of the Na
+-ATPase by 10−9 M BK
after 30 min of incubation (Fig. 6A). The inhibitory effect of
10−9 M BK was reversed by 10−8 M Cph C and 5×10−8 M
U73122 when these were added before BK. On the other hand,
the addition of 10−8 M Cph C or 5×10−8 M U73122 after
15 min of incubation with BK, when activation of the PI-PLCβ/
PKC pathway was complete, did not change the inhibitory ef-
fect of BK on the enzyme activity.
Fig. 6B shows the modulation of BK-stimulated iPLA2 ac-
tivity by an agonist and two antagonists of the PI-PLCβ/PKC
pathway. BK (10−9 M) increased iPLA2 activity, and this effect
was completely abolished by 10−8 M Cph C or 5×10−8 M
U73122. Furthermore, 10−12 M phorbol ester (PMA), an acti-
vator of PKC, increased iPLA2 activity in a similar manner to BK.
These data show that activation of the PI-PLCβ/PKC path-
way is a critical step prior to Ca2+-independent, membrane-
associated iPLA2-mediated inhibition of Na
+-ATPase by BK.
4. Discussion
In this paper we show that BK, through its B2 receptor, has a
dual effect on proximal tubule Na+-ATPase in a time-dependent
Fig. 6. Sequential activation of PI-PLCβ/PKC and iPLA2 pathways. A,
Modulation of the inhibitory effect of 10−9 M BK on Na+-ATPase activity by
10−8 M Cph C and 5×10−8 M U73122. Before BK indicates that inhibitors were
added before 30 min incubation with BK (n=12). After BK indicates that
inhibitors were added after 15 min incubation with BK (n=12). B, Modulation
of the stimulatory effect of 10−9 M BK on PLA2 activity by 10
−8 M Cph C and
5×10−8 M U73122. 10−12 M PMA increased the PLA2 activity in a similar
manner to BK (n=8). Data are shown as means±SE. ⁎Statistically significant
when compared to respective controls ( pb0.05).
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effects depending on the receptorwithwhich it interacts [28]. Two
receptors coupled to GTP binding protein have been described for
BK: B1 and B2 [29]. In a previous paper we showed that BK, via
its B1 receptor, increases proximal tubule Na
+-ATPase activity,
and inhibits this activity through its B2 receptor [8]. However, the
possible involvement of the B1 receptor in the time-dependent
dual effect of BK on proximal tubule Na+-ATPase can be ruled
out because: (1) all experiments were carried out in the presence
of 10−8 M DALBK, a specific antagonist of B1 receptor that
completely abolishes the B1-mediated stimulation of enzyme
activity by BK; and (2) HOE140, a specific antagonist for B2
receptor, abolished both time-dependent stimulatory and inhibi-
tory effects of BK on the enzyme activity.
Furosemide is also well characterized to inhibit the Na+/K+/
2Cl− cotransporter. However, the effect of furosemide observed
in the present work cannot be associated with the inhibition of
this cotransporter because: (a) this cotransporter is not able to
hydrolyze ATP; (b) this cotransporter is not present in the
proximal tubule; and (c) the cotransporter phosphorylated form
has a molecular weight of 170 kDa; the molecular weight of the
Na+-stimulated, furosemide-sensitive ATP driven E–P is
100 kDa [30].Na+-ATPase belongs to the P-type ATPase family and several
studies have shown biochemical differences between this
enzyme and the classical (Na+K+)ATPase [6–8,30,31]. This
enzyme is completely inhibited by furosemide but is insensitive
to ouabain, a classic (Na++K+)ATPase inhibitor. The possible
effect of furosemide in other ATPases can also be ruled out
because it was observed that furosemide does not change the
(Na+ +K+)ATPase, Mg2+-ATPase, Ca2+-ATPase and Ecto-
ATPase activities [7,32]. So, it is plausible to postulate that
furosemide, in the preparation used in the present manuscript,
works as a “specific inhibitor” of Na+-ATPase.We also observed
that bradykinin has the same effect on Na+-ATPase measured by
Na+ stimulation in the presence of ouabain 1 mM. The link
between Na+-stimulated ATPase activity and Na+ transport was
also shown byMalnic et al. [33]. They observed that furosemide
inhibits Na+ reabsorption in the proximal tubule.
It has been demonstrated that ouabain-insensitive Na+-ATPase
is a primary active transporter target for compounds that are
involved in the regulation of renal Na+ excretion, such as the
peptides of the kallikrein–kinin system [10,15,34–36]. Na+-
ATPase is about 10 times less active than (Na+ +K+)ATPase
[31], which suggests that this enzyme may be involved in fine
tuning, whereas (Na+ +K+)ATPase is responsible for most of
the Na+ reabsorption in the proximal tubule. The data reported
in the present paper, together with observations reported by our
group in previous papers, indicate that Na+-ATPase is involved,
at least in part, in the effect of BK on proximal tubule sodium
reabsorption [8,10,36]. In addition, because B2 receptor me-
diates a dual effect of BK on Na+-ATPase, we postulate that this
effect may permit fine tuning of sodium reabsorption in pro-
ximal tubules.
The mechanisms involved in the modulation of sodium re-
absorption in proximal tubule cells by BK are still to be deter-
mined [2,9]. The results obtained in this paper show that: (a) the
stimulatory phase involves activation of the PI-PLCβ/PKC
pathway, and the inhibitory phase involves a Ca2+-independent,
BLM-associated PLA2; (b) prior activation of the PI-PLCβ/PKC
pathway is required for activation of the iPLA2-mediated in-
hibitory phase; and (c) the inhibitory effect of BK depends on the
metabolism of AA by COX. These results represent a new
mechanism of regulation of renal sodium excretion by BK.
In the present manuscript, we used isolated BLMwhich avoids
the possible translocation of PLA2 from cytosol to plasma
membrane after its activation. Furthermore, all experiments were
carried out in the absence of Ca2+. In this way, the involvement of
Ca2+-dependent group IV cPLA2 (α and β) can be ruled out
because its activation involves Ca2+-dependent translocation to
plasmamembranes.On the other hand, cPLA2γ, which belongs to
group IV, lacks a C2 domain (Ca2+-independent) and could be
constitutively associated with cell membrane through a palmi-
toylation site. The molecular weight of cPLA2γ is 61 kDa; we
showed the presence of only one band of 85 kDa in BLM using
polyclonal antibody anti-iPLA2. Furthermore, the observation
that PACOCF3 and BEL abolished both basal and BK-stimulated
PLA2 activity associatedwithBLMcould indicate the presence of
group VI iPLA2 in the proximal tubule BLM. This hypothesis is
strengthened by observation that a BEL-sensitive group VI iPLA2
1322 J.D. Líbano-Soares et al. / Biochimica et Biophysica Acta 1778 (2008) 1316–1323with molecular weight around 85 kDa, has been shown in renal
cortex [26,37–41]. However, the involvement of group IV
cPLA2γ cannot be completely ruled out. Further experiments are
necessary to clarify this issue.
The activation of PLA2 could lead to either an increase or a
decrease in Na+ reabsorption in proximal tubule cells, depending
on the agonist and the cellular distribution of PLA2 [12,42]. It was
observed that BK modulates Ca2+-dependent PLA2 activity in
rabbit isolated proximal tubule; BK-stimulated cPLA2 activity but
decreased Ca2+-dependent, membrane-associated cPLA2 activity
[43]. On the other hand, the role of iPLA2 is still not completely
known. It was proposed that group VI iPLA2 regulates phos-
pholipid turnover, cell growth and apoptosis. In a previous paper,
it was shown that the iPLA2 located in endoplasmic reticulum
plays an important role against oxidant-induced lipid peroxidation
and oncosis in proximal tubules [38]. However, its modulation by
hormones and its involvement in sodiumhomeostasis are yet to be
determined. Here we show that BK induces the activation of
BLM-associated iPLA2 activity. These data agree with the ob-
servation thatBK, via the B2 receptor, inhibitsNa
+ reabsorption in
the proximal tubule, showing a close correlation between sodium
excretion and iPLA2 activation. This result opens up new pos-
sibilities for understanding the role of this enzyme in renal sodium
excretion as well as blood pressure regulation.
The molecular mechanisms involved in the activation of
iPLA2 are poorly understood. In the present study, we observed
that the inhibition of PKC (with Cph C) and PI-PLCβ (with
U73122) abolished the BK-induced activation of PLA2. Fur-
thermore, the phorbol ester, PMA, an activator of PKC, in-
creased the PLA2 activity in a similar manner to BK. Because we
used isolated BLM, the presence of amembrane-associated PKC
pool is required. In a previous paper, we showed that BLM has a
resident pool of PKC activated by phorbol ester and insensitive
to Ca2+ [44]. In a similar way, using membrane fractions of
ventricular myocytes, Steer et al. [45] showed that PMA
increases iPLA2 through activation of a resident pool of PKC.
These results show that PKC is the link between the activation of
PI-PLCβ and Ca2+-independent, membrane-associated PLA2 by
BK. However, there is a question still to be answered: does PKC
mediate the activation of iPLA2 through direct phosphorylation
or is this effect mediated by another protein? Although no phos-
phorylation consensus sequences have been described in iPLA2,
different studies suggest the involvement of phosphorylation in
the regulation of this enzyme [37,40,46–48].
In summary, we have shown that BK, through its B2 recep-
tor, has a dual effect on proximal tubule Na+-ATPase activity,
mediated by the integrated activation of two different pathways:
PI-PLCβ/PKC and iPLA2. These results open new possibilities
in our understanding of the molecular mechanisms underlying
BK regulation of renal sodium excretion and the role of iPLA2
in this process.
Acknowledgments
We thank Dr Martha Sorenson (Instituto de Bioquímica
Médica, Universidade Federal do Rio de Janeiro) for her critical
review of the manuscript. This work was supported by grantsfrom Programa de Apoio ao Desenvolvimento Científico e
Tecnológico (PADCT), Conselho Nacional de Desenvolvimento
Científico e Tecnológico (CNPq), Programa de Apoio a Núcleos
de Excelência (PRONEX/CNPq), Fundação Carlos Chagas Filho
deAmparo à Pesquisa do Estado doRio de Janeiro (FAPERJ) and
Fundação de Amparo à Pesquisa do Estado de São Paulo
(FAPESP). Technical support was provided by Shanserley Leite
do Espírito Santo and Marta Peres Teixeira (CNPq fellowships).
References[1] M. Katori, M. Majima, The renal kallikrein–kinin system: its role as a
safety valve for excess sodium intake, and its attenuation as a possible
etiologic factor in salt-sensitive hypertension, Crit. Rev. Clin. Lab. Sci. 40
(2003) 43–115.
[2] J. Tornel, M.I. Madrid, M. García-Salom, K.J. Wirth, F.J. Fenoy, Role of
kinins in the control of renal papillary blood flow, pressure natriuresis, and
arterial pressure, Circ. Res. 86 (2000) 589–595.
[3] P.A. Ortiz, J.L. Garvin, Intrarenal transport and vasoactive substances in
hypertension, Hypertension 38 (2001) 621–624.
[4] E. Ferraille, A. Doucet, Sodium–potassium-adenosinetriphosphatase-
dependent sodium transport in the kidney: hormonal control, Physiol.
Rev. 81 (2001) 345–418.
[5] G. el Mernissi, C. Barlet-Bas, C. Khadouri, S. Marsy, L. Cheval, A.
Doucet, Characterization and localization of ouabain-insensitive Na-
dependent ATPase activities along the rat nephron, Biochim. Biophys.
Acta 1064 (1991) 205–211.
[6] F. Proverbio, T. Proverbio, R. Marin, Na+-ATPase is a different entity from
the (Na++K+)-ATPase in rat kidney basolateral plasma membranes,
Biochim. Biophys. Acta 858 (1986) 202–205.
[7] C. Caruso-Neves, S.A. Coelho-Souza, D. Vives, G. Goes, L.S. Lara, A.G.
Lopes, Modulation of ouabain-insensitive Na(+)-ATPase activity in the
renal proximal tubule byMg(2+), MgATP and furosemide, Int. J. Biochem.
Cell Biol. 34 (2002) 1586–1593.
[8] C. Caruso-Neves, A.S. Siqueira, G. Iso-Cohen, A.G. Lopes, Bradykinin
modulates the ouabain-insensitive Na+-ATPase activity from basolateral
membrane of the proximal tubule, Biochim. Biophys. Acta 1431 (1999)
483–491.
[9] R.L. Hébert, D. Regoli, H. Xiong, M.D. Breyer, G.E. Plante, Bradykinin
B2 type receptor activation regulates fluid and electrolyte transport in the
rabbit kidney, Peptides 26 (2005) 1308–1316.
[10] C. Caruso-Neves, A.T. Malaquias, F.F. Lóss, V.M. Corrêa da Costa, V.O.
Gomes, A.G. Lopes, Bradykinin B1 receptor stimulates the proximal
tubule Na(+)-ATPase activity through protein kinase C pathway, Regul.
Pept. 115 (2003) 195–201.
[11] C. Blais Jr., F. Marceau, J.L. Rouleau, A. Adam, The kallikrein–kininogen–
kinin system: lessons from the quantification of endogenous kinins, Peptides
21 (2000) 1903–1940.
[12] A.G. Lopes, A.C. Soares, D.P. Santos, M.S. Fernandes, L.R. Leao-
Ferreira, E. Quintana-Gomes, C. Caruso-Neves, PLA2/PGE2 are in-
volved in the inhibitory effect of bradykinin on the angiotensin-(1-7)-
stimulated Na(+)-ATPase activity of the proximal tubule, Regul. Pept.
117 (2004) 37–41.
[13] D.A. Six, E.A. Dennis, The expanding superfamily of phospholipase A(2)
enzymes: classification and characterization, Biochim. Biophys. Acta 1488
(2000) 1–19.
[14] A.M. De Souza, A.G. Lopes, C.P. Pizzino, R.N. Fossari, N.C. Miguel, P.
Cardozo, R. Abi-Abib, M.S. Fernandes, D.P. Santos, C. Caruso-Neves,
Angiotensin II and angiotensin-(1-7) inhibit the inner cortex Na+-ATPase
activity through AT2 receptor, Regul. Pept. 120 (2004) 167–175.
[15] L.B. Rangel, A.G. Lopes, L.S. Lara, T.L. Carvalho, I.V. Silva, M.M.
Oliveira, M. Einicker-Lamas, A. Vieyra, L. Nogaroli, C. Caruso-Neves,
PI-PLCbeta is involved in the modulation of the proximal tubule Na+-
ATPase by angiotensin II, Regul. Pept. 127 (2005) 177–182.
1323J.D. Líbano-Soares et al. / Biochimica et Biophysica Acta 1778 (2008) 1316–1323[16] L.B. Rangel, C. Caruso-Neves, L.S. Lara, A.G. Lopes, Angiotensin II sti-
mulates renal proximal tubule Na(+)-ATPase activity through the activation
of protein kinase C, Biochim. Biophys. Acta 1564 (2002) 310–316.
[17] J.C. Maia, S.L. Gomes, M.H. Juliani, in: C. Morel (Ed.), Preparation of
(gamma-32P)- and (alpha-32P)-nucleotide Triphosphates with High Specific
Activity, Fundação Oswaldo Cruz, Rio de Janeiro, 1993, pp. 139–146.
[18] S.M. Grassl, P.S. Aronson, Na+/HCO3-co-transport in basolateral mem-
brane vesicles isolated from rabbit renal cortex, J. Biol. Chem. 261 (1986)
8778–8783.
[19] O.H. Lowry, N.J. Rosebrough, A.L. Farr, R.J. Randall, Protein measure-
ment with the Folin phenol reagent, J. Biol. Chem. 193 (1951) 265–275.
[20] C. Grubmeyer, H.S. Penefsky, The presence of two hydrolytic sites on beef
heart mitochondrial adenosine triphosphatase, J. Biol. Chem. 256 (1981)
3718–3227.
[21] C. Caruso-Neves, S.A. Coelho-Souza, D. Vives, G. Goes, L.S. Lara, A.G.
Lopes, Modulation of ouabain-insensitive Na(+)-ATPase activity in the
renal proximal tubule byMg(2+), MgATP and furosemide, Int. J. Biochem.
Cell Biol. 34 (2002) 1586–1593.
[22] H.C. Yang, M. Mosior, C.A. Johnson, Y. Chen, E.A. Dennis, Group-
specific assays that distinguish between the four major types of mam-
malian phospholipase A2, Anal. Biochem. 269 (1999) 278–288.
[23] A.T. Malaquias, M.M. Oliveira, Phospholipid signalling pathways in
Trypanosoma cruzi growth control, Acta. Trop. 73 (1999) 93–108.
[24] M.E. Moreau, N. Garbacki, G. Molinaro, N.J. Brown, F. Marceau, A.
Adam, The kallikrein–kinin system: current and future pharmacological
targets, J. Pharmacol. Sci. 99 (2005) 6–38.
[25] J. Balsinde, M.A. Balboa, Cellular regulation and proposed biological
functions of group VIA calcium-independent phospholipase A2 in acti-
vated cells, Cell. Signal. 17 (2005) 1052–1062.
[26] Z. Ma, X. Wang, W. Nowatzke, S. Ramanadham, J. Turk, Human pancreatic
islets express mRNA species encoding two distinct catalytically active
isoforms of group VI phospholipase A2 (iPLA2) that arise from an exon-
skipping mechanism of alternative splicing of the transcript from the iPLA2
gene on chromosome 22q13.1, J. Biol. Chem. 274 (1999) 9607–9616.
[27] H.C. Yang, M. Mosior, B. Ni, E.A. Dennis, Regional distribution, on-
togeny, purification, and characterization of the Ca2+-independent phos-
pholipase A2 from rat brain, J. Neurochem. 73 (1999) 1278–1287.
[28] R. Couture, M. Harrisson, R.M. Vianna, F. Cloutier, Kinin receptors in
pain and inflammation, Eur. J. Pharmacol. 429 (2001) 161–176.
[29] L.M. Leeb-Lundberg, F. Marceau, W. Muller-Esterl, D.J. Pettibone, B.L.
Zuraw, International union of pharmacology, Classification of the kinin
receptor family: from molecular mechanisms to pathophysiological con-
sequences, XLV, 2005, pp. 27–77.
[30] A.M. De Souza, T.L. Carvalho, P.M. Sabino, D. Vives, C.F. Fontes, A.G.
Lopes, C. Caruso-Neves, Characterization and partial isolation of ouabain-
insensitive Na+-ATPase in MDCK I cells, Biochimie 89 (2007) 1425–1432.
[31] F. Proverbio, R. Marín, T. Proverbio, The “second” sodium pump and cell
volume, Curr. Membr. Transp. 34 (1989) 105–119.
[32] M. de Souza Leite, R. Thomaz, F.V. Fonseca, R. Panizzutti, A.E. Vercesi, J.R.
Meyer-Fernandes, Trypanosoma brucei brucei: biochemical characterization
of ecto-nucleoside triphosphate diphosphohydrolase activities, Exp. Para-
sitol. 115 (2007) 315–323.
[33] G. Malnic, H. Enoikibara, M. Mello Aires, F. Lacaz Vieira, Effect of
furosemid and NaCl-loading on chloride excretion in single nephrons of rat
kidneys, Pflugers Arch. 309 (1969) 21–37.[34] L.S. Lara, F. Cavalcante, F. Axelband, A.M. De Souza, A.G. Lopes, C.
Caruso-Neves, Involvement of the Gi/o/cGMP/PKG pathway in the AT2-
mediated inhibition of outer cortex proximal tubule Na+-ATPase by Ang-
(1-7), Biochem. J. 395 (2006) 183–190.
[35] C. Caruso-Neves, D. Vives, C. Dantas, C.M. Albino, L.M. Fonseca, L.S.
Lara, M. Iso, A.G. Lopes, Ouabain-insensitive Na+-ATPase of proximal
tubules is an effector for urodilatin and atrial natriuretic peptide, Biochim.
Biophys. Acta 1660 (2004) 93–98.
[36] C. Caruso-Neves, K. Provenzano, F.F. Luz, F.M. Santos, M.S. Fernandes,
L.R. Leao-Ferreira, A.G. Lopes, Bradykinin counteracts the stimulatory
effect of angiotensin-(1-7) on the proximal tubule Na+-ATPase activity
through B2 receptor, Regul. Pept. 110 (2003) 207–212.
[37] H.K. Tay, A.J. Melendez, Fcgamma RI-triggered generation of arachidonic
acid and eicosanoids requires iPLA2 but not cPLA2 in human monocytic
cells, J. Biol. Chem. 279 (2004) 22505–22513.
[38] B.S. Cummings, J. Mchowat, R.G. Schnellmann, Role of an endoplasmic
reticulum Ca2+-independent phospholipase A(2) in oxidant-induced renal
cell death, Am. J. Physiol., Renal Physiol. 283 (2002) F492–F498.
[39] P.K. Larsson Forsell, G. Runarsson, M. Ibrahim, M. Bjorkholm, H.E.
Claesson, On the expression of cytosolic calcium-independent phospho-
lipase A2 (88 kDa) in immature and mature myeloid cells and its role in
leukotriene synthesis in human granulocytes, FEBS Lett. 434 (1998)
295–299.
[40] H. Tanaka, R. Takeya, H. Sumimoto, A novel intracellular membrane-
bound calcium-independent phospholipase A(2), Biochem. Biophys. Res.
Commun. 272 (2000) 320–326.
[41] D.J. Mancuso, C.M. Jenkins, R.W. Gross, The genomic organization,
complete mRNA sequence, cloning, and expression of a novel human in-
tracellular membrane-associated calcium-independent phospholipase A(2),
J. Biol. Chem. 275 (2000) 9937–9945.
[42] B.N. Becker, H.F. Cheng, R.C. Harris, Apical ANG II-stimulated PLA2
activity and Na+ flux: a potential role for Ca2+-independent PLA2, Am. J.
Physiol. 273 (1997) F554–F562.
[43] S. Harwalkar, C.H. Chang, N.O. Dulin, J.G. Douglas, Role of phos-
pholipase A2 isozymes in agonist-mediated signaling in proximal tubular
epithelium, Hypertension 31 (1998) 809–814.
[44] L.B. Rangel, A.T. Malaquias, L.S. Lara, I.V. Silva, A.M. De Souza, A.G.
Lopes, C. Caruso-Neves, Protein kinase C-induced phosphorylation mo-
dulates the Na(+)-ATPase activity from proximal tubules, Biochim. Biophys.
Acta 1512 (2001) 90–97.
[45] S.A. Steer, K.C. Wirsig, M.H. Creer, D.A. Ford, J. McHowat, Regulation
of membrane-associated iPLA2 activity by a novel PKC isoform in
ventricular myocytes, Am. J. Physiol. 283 (2002) C1621–C1626.
[46] S. Akiba, S.Mizunaga, K. Kume,M.Hayama, T. Sato, Involvement of group
VI Ca2+-independent phospholipase A2 in protein kinase C-dependent ar-
achidonic acid liberation in zymosan-stimulated macrophage-like P388D1
cells, J. Biol. Chem. 274 (1999) 19906–19912.
[47] S. Akiba, S. Ohno, M. Chiba, K. Kume, M. Hayama, T. Sato, Protein
kinase Calpha-dependent increase in Ca2+-independent phospholipase A2
in membranes and arachidonic acid liberation in zymosan-stimulated
macrophage-like P388D1 cells, Biochem. Pharmacol. 63 (2002)
1969–1977.
[48] C.R. Yellaturu, G.N. Rao, A requirement for calcium-independent phos-
pholipase A2 in thrombin-induced arachidonic acid release and growth in
vascular smooth muscle cells, J. Biol. Chem. 278 (2003) 43831–43837.
